Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma

ALK-positive Anaplastic Large Cell Lymphoma (ALCL) represents a subset of Non-Hodgkin Lymphoma whose treatment benefited from crizotinib development, a dual ALK/MET inhibitor. Crizotinib blocks ALK-triggered pathways such as PI3K/AKT/mTOR, indispensable for survival of ALK-driven tumors. Despite the...

Descripción completa

Detalles Bibliográficos
Autores principales: Redaelli, Sara, Ceccon, Monica, Antolini, Laura, Rigolio, Roberta, Pirola, Alessandra, Peronaci, Marco, Gambacorti-Passerini, Carlo, Mologni, Luca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5341951/
https://www.ncbi.nlm.nih.gov/pubmed/27662658
http://dx.doi.org/10.18632/oncotarget.12128

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5341951/
https://www.ncbi.nlm.nih.gov/pubmed/27662658
http://dx.doi.org/10.18632/oncotarget.12128

Ejemplares similares